市場調查報告書

腎上腺腦白質失養症(ALD)- 流行病學預測 2030年

Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 629049
出版日期 內容資訊 英文 83 Pages
商品交期: 最快1-2個工作天內
價格
腎上腺腦白質失養症(ALD)- 流行病學預測 2030年 Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030
出版日期: 2020年03月01日內容資訊: 英文 83 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的腎上腺腦白質失養症(ALD)2017年的罹患數估算為5萬5,242人。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的腎上腺腦白質失養症(ALD)市場相關調查,疾病概要,主要7個國家的流行病學趨勢,性別、各類型的患病數變化與預測等總括性彙整。

目錄

第1章 重要洞察

第2章 腎上腺腦白質失養症(ALD):流行病學概要

  • 腎上腺腦白質失養症(ALD)的分佈(實在數值)
  • 腎上腺腦白質失養症(ALD)的分佈(預測值)

第3章 腎上腺腦白質失養症(ALD):疾病背景和概要

  • 簡介
  • 臨床性方面
  • 原因
  • 遺傳模式
  • 症狀
  • 病因與病情生理
  • 診斷

第4章 流行病學和患者數

  • 主要調查結果
  • 流行病學的方法論
  • 關鍵意見領袖的意見
  • 主要7個國家的ALD的總患病數

第5章 美國的流行病學

  • 假設和根據
  • 總患病數
  • 患病數:性別
  • 診斷患病數:性別
  • 診斷患病數:各類型
  • 男性的診斷患病數:各類型

第6章 歐洲5個國家的流行病學

  • 德國的流行病學
    • 假設和根據
    • 總患病數
    • 患病數:性別
    • 診斷患病數:性別
    • 診斷患病數:各類型
  • 法國的流行病學
  • 義大利的流行病學
  • 西班牙的流行病學
  • 英國的流行病學

第7章 日本的流行病學

  • 假設和根據
  • 總患病數
  • 患病數:性別
  • 診斷患病數:性別
  • 診斷患病數:各類型

第8章 附錄

  • 出處
  • 報告方法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0467

Overview

DelveInsight's 'Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adrenoleukodystrophy (ALD) Understanding

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. There are three basic forms of ALD: neonatal, childhood, and adult-onset. The childhood ALD is the classical and the most severe form leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome). The adult-onset, called AMN is mild, progresses slowly, and usually appears in people aged 21-35 years.

Adrenoleukodystrophy (ALD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM. The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030.

Adrenoleukodystrophy (ALD) Detailed Epidemiology Segmentation

As per DelveInsight's analysis, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242. The analysis also shows that a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries during the study period (2017-2030).

Based on the type of ALD, it was also assessed that majority of the patients suffer from Cerebral ALD (CALD), with 458 cases observed in the US, in 2017, while Adrenomyeloneuropathy (AMN) and Addison Disease account for nearly 305, and 124 cases of the total diagnosed male symptomatic ALD population. Out of the total diagnosed male cases, CALD includes 1,173 cases, which is further divided based on age, i.e., Childhood CALD (904 cases), Adolescent CALD (171 cases), and Adult CALD (98 cases) in 2017 in the US.

Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,699 cases, followed by France and the United Kingdom. On the other hand, Spain had the lowest diagnosed prevalent population of 1,041 in 2017. Japan had 2,155 diagnosed prevalent cases for ALD in 2017.

Scope of the Report

  • The report covers the descriptive overview of Adrenoleukodystrophy, explaining its clinical aspects, symptoms, causes, inheritance pattern, pathophysiology, and diagnosis.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Adrenoleukodystrophy.
  • The report helps to recognize the growth opportunities in the 7MM countries for the patient population.
  • The report provides the segmentation of the disease epidemiology by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM.

Report Highlights

  • 11-Year Forecast of Adrenoleukodystrophy epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Adrenoleukodystrophy
  • Prevalent Cases according to segmentation: Gender-specific prevalence
  • Diagnosed cases of Adrenoleukodystrophy according to segmentation: Gender-specific diagnosed prevalence and type-specific diagnosed prevalence of ALD in male

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of Adrenoleukodystrophy?
  • What are the key findings of the Adrenoleukodystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Adrenoleukodystrophy across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2017-2030)?

Reasons to buy

The Adrenoleukodystrophy report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Adrenoleukodystrophy market.
  • Quantify patient populations in the 7MM Adrenoleukodystrophy market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adrenoleukodystrophy therapeutics in each of the markets covered.
  • Understand the magnitude of the Adrenoleukodystrophy population by its severity.
  • The Adrenoleukodystrophy epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Adrenoleukodystrophy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance

  • 2.1. Total Epidemiology Share (%) Distribution of ALD in 2017
  • 2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Clinical aspects of ALD
  • 3.3. Causes of ALD
  • 3.4. Inheritance pattern of ALD
  • 3.5. ALD-Symptoms
  • 3.6. Pathogenesis and Pathophysiology of ALD
  • 3.7. Diagnosis
    • 3.7.1. ALD Newborn Screening
    • 3.7.2. Tools for evaluating Cerebral ALD
    • 3.7.3. Diagnostic algorithm
    • 3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Epidemiology Methodology
  • 4.3. KOL Views
  • 4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
  • 5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
  • 5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
  • 5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
    • 6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
    • 6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
    • 6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
    • 6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
    • 6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
    • 6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
    • 6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
    • 6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
    • 6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
    • 6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
    • 6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
    • 6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
    • 6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
    • 6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
    • 6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
  • 7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
  • 7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
  • 7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance

  • 2.1. Total Epidemiology Share (%) Distribution of ALD in 2017
  • 2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Clinical aspects of ALD
  • 3.3. Causes of ALD
  • 3.4. Inheritance pattern of ALD
  • 3.5. ALD-Symptoms
  • 3.6. Pathogenesis and Pathophysiology of ALD
  • 3.7. Diagnosis
    • 3.7.1. ALD Newborn Screening
    • 3.7.2. Tools for evaluating Cerebral ALD
    • 3.7.3. Diagnostic algorithm
    • 3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Epidemiology Methodology
  • 4.3. KOL Views
  • 4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
  • 5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
  • 5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
  • 5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
    • 6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
    • 6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
    • 6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
    • 6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
    • 6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
    • 6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
    • 6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
    • 6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
    • 6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
    • 6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
    • 6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
    • 6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
    • 6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
    • 6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
    • 6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
  • 7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
  • 7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
  • 7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance

  • 2.1. Total Epidemiology Share (%) Distribution of ALD in 2017
  • 2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Clinical aspects of ALD
  • 3.3. Causes of ALD
  • 3.4. Inheritance pattern of ALD
  • 3.5. ALD-Symptoms
  • 3.6. Pathogenesis and Pathophysiology of ALD
  • 3.7. Diagnosis
    • 3.7.1. ALD Newborn Screening
    • 3.7.2. Tools for evaluating Cerebral ALD
    • 3.7.3. Diagnostic algorithm
    • 3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Epidemiology Methodology
  • 4.3. KOL Views
  • 4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
  • 5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
  • 5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
  • 5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
    • 6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
    • 6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
    • 6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
    • 6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
    • 6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
    • 6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
    • 6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
    • 6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
    • 6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
    • 6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
    • 6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
    • 6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
    • 6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
    • 6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
    • 6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
  • 7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
  • 7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
  • 7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1 ALD Phenotypes in Males
  • Table 2 Phenotype in Female ALD carriers
  • Table 3 The ALD Phenotypes
  • Table 4 MRI Severity Scale
  • Table 5 MRI Severity Rating
  • Table 6 Neurological Function Score (NFS Score)
  • Table 7 X-linked Adrenoleukodystrophy-Disability Rating Scale (ALD-DRS)
  • Table 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017-2030)
  • Table 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017-2030)
  • Table 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017-2030)
  • Table 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017-2030)
  • Table 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017-2030)
  • Table 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017-2030)
  • Table 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017-2030)
  • Table 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017-2030)
  • Table 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017-2030)
  • Table 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017-2030)
  • Table 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017-2030)
  • Table 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017-2030)
  • Table 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017-2030)
  • Table 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017-2030)
  • Table 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017-2030)
  • Table 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017-2030)
  • Table 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017-2030)
  • Table 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017-2030)
  • Table 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017-2030)
  • Table 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017-2030)
  • Table 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017-2030)
  • Table 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017-2030)
  • Table 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017-2030)
  • Table 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017-2030)
  • Table 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017-2030)
  • Table 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017-2030)
  • Table 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017-2030)
  • Table 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017-2030)
  • Table 36 Type-Specific Diagnosed Prevalence of ALD in Males Japan (2017-2030)

List of Figures

  • Figure 1 Evolution of Phenotypes in ALD
  • Figure 2 Clinical Spectrum of ALD
  • Figure 3 Inheritance spectrum of ALD
  • Figure 4 Pathogenesis of VLCFA
  • Figure 5 Principles of ALD 3-tier screening
  • Figure 6 Diagnostic algorithm for diagnosis of adrenoleukodystrophy
  • Figure 7 ALD Screening Decision Tree
  • Figure 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017-2030)
  • Figure 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017-2030)
  • Figure 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017-2030)
  • Figure 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017-2030)
  • Figure 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017-2030)
  • Figure 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017-2030)
  • Figure 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017-2030)
  • Figure 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017-2030)
  • Figure 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017-2030)
  • Figure 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017-2030)
  • Figure 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017-2030)
  • Figure 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017-2030)
  • Figure 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017-2030)
  • Figure 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017-2030)
  • Figure 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017-2030)
  • Figure 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017-2030)
  • Figure 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017-2030)
  • Figure 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017-2030)
  • Figure 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017-2030)
  • Figure 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017-2030)
  • Figure 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017-2030)
  • Figure 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017-2030)
  • Figure 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017-2030)
  • Figure 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017-2030)
  • Figure 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017-2030)
  • Figure 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017-2030)
  • Figure 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017-2030)
  • Figure 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017-2030)
  • Figure 36 Type-Specific Diagnosed Prevalence of ALD in Males in Japan (2017-2030)